Lexaria Bioscience Corp. Announces That The Co's Anticipated Submission Of An Investigational New Drug Application With The U.S. FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Is Expected To Be Filed Within ~45 Days
Lexaria Bioscience Corp. Announces That The Co's Anticipated Submission Of An Investigational New Drug Application With The U.S. FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Is Expected To Be Filed Within ~45 Days
Lexaria Bioscience Corp. 宣布，该公司预计将在约45天内向美国食品药品管理局提交其计划中的美国1b期高血压临床试验的在研新药申请
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. Phase 1b Hypertension Clinical Trial is expected to be filed within approximately 45 days.
药物递送平台领域的全球创新者Lexaria Bioscience Corp.（纳斯达克股票代码：LEXXW）（“公司” 或 “Lexaria”）宣布，该公司预计将在大约45天内向美国食品药品监督管理局（“FDA”）提交计划中的美国1b期高血压临床试验的在研新药（“IND”）申请。
As previously announced, this filing was regrettably delayed while Lexaria awaited overdue documentation from one of its key raw material suppliers. Lexaria is pleased to announce that the supplier in question has updated much of this documentation with Lexaria and directly with...
正如先前宣布的那样，令人遗憾的是，在Lexaria等待其主要原材料供应商之一的逾期文...
登录免费看全文
登录/注册